Mallinckrodt’s spending on political donations and lobbying comes as the drug industry as a whole beefs up its Capitol Hill presence.
NYS Entity Status
NYS Filing Date
MAY 19, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - LA VIE R&R, INC.
AROUND THE WEB
- A Drug Maker Spends Big in Washington to Make Itself Heard
By JAY HANCOCK, ELIZABETH LUCAS and SYDNEY LUPKIN - Friday Jul 21, 2017
- Rochester judge accused of violating probation
By email@example.com (Fox News Online) - Thursday Aug 3, 2017
- Welcome to the softer side of gutted Sears stores
By John Biggs - Monday Jun 12, 2017
If there is any indication of the cultural import and effect of the “millennials” – a term I dislike for reasons I will explain later – look no further than America’s malls. The Baby Boomer hubris and NIMBYism that sent malls into further and further orbits from city centers has come home to roost and it promises to change the face of retail in a big way. First,… Read More
- Abbvie’s hep C drug pricing threatens Gilead’s dominance
By Max Nisen - Tuesday Aug 8, 2017
Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.
- Charlottesville marcher: 'I'm not a hateful person'
By Rochester (N.Y.) Democrat and Chronicle - By Rochester (N.Y.) Democrat and Chronicle - Thursday Aug 17, 2017
When Jarrod Kuhn returned home to Honeoye Falls, N.Y., on Sunday after his trip to Charlottesville, Va., he was confronted by a harsh reality.